Université de Strasbourg, IPHC, 23 rue du Loess, 67037 Strasbourg, France.
Dalton Trans. 2015 Mar 21;44(11):4845-58. doi: 10.1039/c4dt02911a.
Several limitations of (18)F and other non-metallic isotopes have been emphasized by the development of macromolecular biotargeting agents for cancer, including peptides, antibodies, fragments and oligonucleotides, which typically have biological half-lives that are much longer than the radioactive half-life of (18)F. Based on the (18)F-FDG success story, we can wonder whether all critical criteria are or can be fulfilled for the radiometallated bioconjugates to start out from the crowd and which metals have the best chance of success. In this paper we give a brief overview of radiometal isotopes having the potential for PET imaging in terms of physical properties, production capacity and associated chemistry.
为了癌症的治疗，大分子生物靶向药物（包括肽、抗体、片段和寡核苷酸）得到了发展，这使得（18）F 和其他非金属同位素的应用受到了一些限制。这些生物靶向药物的生物半衰期通常比（18）F 的放射性半衰期长得多。基于（18）F-FDG 的成功案例，我们不禁要问，对于那些放射性金属生物缀合物来说，是否所有的关键标准都已经满足或者可以满足，从而使它们脱颖而出，以及哪些金属最有成功的机会。在本文中，我们将简要概述在物理性质、生产能力和相关化学方面具有正电子发射断层扫描成像潜力的放射性金属同位素。
